Introduction
Serum CA 19-9 (carbohydrate antigen 19-9) is a tumor marker that is expressed as a monosialoganglioside and a mucosal protein in tissues. CA 19-9, which is secreted into the blood, saliva, bronchial secretions, and in stomach and bile fluids, has found application in the follow-up of recurrence of certain malignant diseases post tumor resection, primarily in the biliopancreatic malignancies (1) . However, CA 19-9 may also exhibit elevated levels in non-malignant diseases, such as biliary obstruction, chronic viral hepatitis, chronic pancreatitis, or idiopathic pulmonary fibrosis, as its specificity is not very high (2) (3) (4) (5) . Although there is no definite limit for CA 19-9 elevation that occurs in benign and malignant diseases, cer-DOI: 10.25179/tjem.2018-63123
Serum CA 19-9 (carbohydrate antigen 19-9) is a tumor marker with monosialoganglioside structure. Its levels are measured frequently for screening purposes in daily practice by physicians, while its main application is in the study of tumor recurrence and the follow-up of the recurrences. Although significant elevation in the levels of CA 19-9 indicates malignancy, an underlying malignant disease may not always be determined, and benign pathologies may also be observed. A 45-year-old female patient who was undergoing a follow-up for Hashimoto's thyroiditis applied to our clinic with complaints of fatigue, tiredness, and hair loss. Elevations in the levels of both thyroid-stimulating hormone (TSH) and CA 19-9 were observed. The levels of TSH and CA 19-9 were observed to be normal after the patient was treated for hypothyroidism, and the results of the analysis conducted for malignancy were also determined to be normal. On the basis of the present case study, we propose that hypothyroidism should be considered while making a differential diagnosis for patients with elevated levels of CA 19-9. (2, 6, 7) . The earlier studies have revealed that CA 19-9 elevation may also occur in Hashimoto's thyroiditis in proportion to the elevation in the thyroid-stimulating hormone (TSH), even in the absence of any underlying malignant disease (8, 9) . The present study was, therefore, aimed at demonstrating the relationship between the levels of CA 19-9 and thyroid function disorder in a patient undergoing a follow-up for the diagnosis of Hashimoto's thyroiditis.
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Case Report
A 45-year-old female patient, who had been undergoing a follow-up for the diagnosis of Hashimoto's thyroiditis for 20 years, applied to our clinic with complaints of fatigue, tiredness, and hair loss. She had a history of smoking (five packs/year), although she had quit and been a non-smoker for the last ten years. She had no known diseases, her deceased mother had suffered from malignant esophagus neoplasm, and her father had been diagnosed with hypertension. The patient stated that she was on a replacement treatment with levothyroxine at a daily dose of 100 µg when she applied to our clinic. The findings of her physical examination were normal, except for the dry skin and frozen glance. In the laboratory analyses, it was determined that the TSH level was 17.08 µIU/mL (normal range: 0.55-4.78), serum free thyroxin level was 0.7 ng/mL (0.78-1.48), and the level of anti-thyroid peroxidase antibody was 720 U/mL (0-35). The annual routine controls conducted for screening purposes revealed high (52 U/mL) CA 19-9 levels (normal: <30.9). The CA 19-9 levels were determined to be high even on repeated measurements (Figure 1 ). The levels of carcinoembryonic antigen, carbohydrate antigen 15-3, carbohydrate antigen 125, alpha fetoprotein, and serum free triiodothyronine were observed to be within the normal limits, and the renal function tests and the liver function tests were also observed to be normal. She, therefore, consulted with the relevant department regarding the elevated levels of CA 19-9, following which, whole-body positron-emission tomography/computed tomography analysis was performed as the results of certain examinations such as mammography and upper gastrointestinal endoscopy were observed to be normal, and no increased metabolic activity uptake was determined for any organ. Physical examination, laboratory analyses, and imaging methods could provide no explanation for the elevated Ca-19-9 levels, and it was considered that the possible reason for the elevation in the Ca-19-9 levels was hypothyroidism. The detailed study of the medical history of this patient with apparent hypothyroidism revealed that she had been using her medication irregularly for the last one month. Subsequently, her daily dose of levothyroxine was increased to 117.85 µg, and she was scheduled for a control visit six weeks later. Investigations in the control visit registered a significant decrease in the initial complaints of fatigue, tiredness, and hair loss. Laboratory analysis determined that she was euthyroid. A decrease in the levels of CA 19-9, which reached 8.2 U/mL, was observed to accompany this improvement in the thyroid function (Figure 1 ).
Discussion
The American Association of Clinical Oncology has suggested that tumor markers should not be used in research on malignancies as even though they are relatively high in sensitivity, they exhibit low specificity (8) .
Tumor markers are nonetheless studied frequently with the belief that the unusually high values of the markers may assist in identifying malignancies. However, elevation in the levels of CA 19-9 (a tumor marker) may also be observed in benign diseases, as occurred in the case reported in the present study. Such a situation may cause anxiety to both the clinician and the patient, and may lead to unnecessary screening analyses. In the case reported in the present study, the reduced levels of CA 19-9 post the treatment for hypothyroidism demonstrated that the elevated value observed initially was not a result of any underlying malignancy. The literature indicates that thyroiditis may increase the levels of CA 19-9, Hashimoto's thyroiditis may elevate the CA 19-9 levels without disturbing the thyroid function tests, and an increase in the CA 19-9 levels may also occur in benign or malignant thyroid diseases (8, (10) (11) (12) (13) (14) (15) . However, contrary data were also reported suggesting that there was no relationship between Hashimoto's thyroiditis and CA 19-9 levels. In a study conducted in 2009 by Sezer et al., 71 patients with a diagnosis of Hashimoto's thyroiditis were examined, and no statistically significant difference was observed in the levels of CA 19-9 between the euthyroid and hypothyroid subjects. However, the number of patients included in that study was not reported, and no correlation was addressed between the serum CA 19-9 levels and TSH levels (16) . Although the influence of thyroid diseases on CA 19-9 elevation has not been elucidated to date, it is commonly believed to be multifactorial (9) . A previous study used immunohistochemical staining to demonstrate that the inflamed thyroid tissue produced CA 19-9 (11). However, CA 19-9 elevation could not be demonstrated in all the cases of inflammatory thyroid disease. The association between thyroid diseases and CA 19-9 levels remains a mystery due to a number of reasons, such as lack of CA 19-9 elevation in certain cases of thyroiditis, the observed elevations not always being in proportion to thyroid function disorder, and the complete absence of CA 19-9 elevation in certain malignant thyroid diseases (16) . Therefore, it is suggested that screening for thyroid diseases in addition to the routine screening parameters would serve as a suitable approach to diagnosis for the patients exhibiting CA 19-9 elevations. In addition, further studies investigating the association between CA 19-9 and thyroid diseases are required to elucidate the details of this association. Informed consent of the patient was obtained for the case report.
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